 |
International Journal for Research Trends and Innovation
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-3315 | Impact factor: 8.14 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.14 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
|
Issue: March 2026
Volume 11 | Issue 3
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.14
Issue per Year : 12
Volume Published : 11
Issue Published : 118
Article Submitted : 21470
Article Published : 8508
Total Authors : 22383
Total Reviewer : 805
Total Countries : 157
Indexing Partner
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | PHARMACOGENOMICS OF TYPE-2 ANTI-DIABETICS |
| Authors Name: | Puneet Kumar , Swati Thakur |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJRTI_189771
|
| Published Paper Id: | IJRTI2404149 |
| Published In: | Volume 9 Issue 4, April-2024 |
| DOI: | |
| Abstract: | Diabetes is the basis for the definition of Hyperglycemia. Determining the genetic etiology of certain monogenic forms of diabetes can significantly alter treatment, allowing patients to switch from insulin to sulfonylureas. But type 2 diabetes accounts for the majority of cases of diabetes. Our understanding of the various subtypes of monogenic diabetes mellitus and the complex etiology of type 2 diabetes mellitus (T2DM) has significantly improved as a result of genomic investigations. Hyperglycemia is a complication of type 2 diabetes mellitus (T2DM), a complicated metabolic disease marked by decreased insulin supply and action. Pharmacogenomics, the study of how a person's genetic composition affects how they respond to medications, has become a viable strategy to maximize therapeutic results in the treatment of type 2 diabetes. In the context of type 2 diabetes, this abstract examines the emerging field of pharmacogenomics, identifying significant genetic variations linked to heterogeneity in drug response and their potential clinical consequences. The inability of other tissue cells to respond to insulin and use blood glucose, as well as the malfunction of pancreatic β-cells in secreting insulin, are signs of a metabolic imbalance in DMT2. But in recent times, thanks to developments in genomics and molecular analysis the substantial evidence that has been gathered up to this point regarding the pharmacogenetics of metformin, sulfonylureas, thiazolidinedione is reviewed in this review. Type 2 diabetes mellitus (T2DM) is a common disease whose incidence is rising quickly throughout the world. Controlling blood sugar levels and preventing the worsening of glycemic symptoms are the two main objectives of T2DM treatment. This article examines the clinical evidence for pharmacogenomics, the drug classes that are frequently prescribed and affected by known pharmacogenes, testing expenses, research obstacles, and requirements for clinical implementation. |
| Keywords: | |
| Cite Article: | "PHARMACOGENOMICS OF TYPE-2 ANTI-DIABETICS", International Journal for Research Trends and Innovation (www.ijrti.org), ISSN:2455-2631, Vol.9, Issue 4, page no.1109 - 1119, April-2024, Available :http://www.ijrti.org/papers/IJRTI2404149.pdf |
| Downloads: | 000205270 |
| ISSN: |
2456-3315 | IMPACT FACTOR: 8.14 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.14 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID: IJRTI2404149
Registration ID:189771
Published In: Volume 9 Issue 4, April-2024
DOI (Digital Object Identifier):
Page No: 1109 - 1119 Country: Mandi, Himachal Pradesh, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijrti.org/viewpaperforall?paper=IJRTI2404149 Published Paper PDF: https://www.ijrti.org/papers/IJRTI2404149 |
| Share Article: | |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijrti.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-3315
Impact Factor: 8.14 and ISSN APPROVED,
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
| Providing A digital object identifier by DOI.ONE How to Get DOI? |
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Join RMS/Earn 300
WhatsApp
Click Here
Click Here
Indexing Partner |
|||
| Copyright © 2026 - All Rights Reserved - IJRTI | |||